Nanobiotix
NBTX
11 hedge funds and large institutions have $81.3M invested in Nanobiotix in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
14.15% more ownership
Funds ownership: 0% → 14.15% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$24.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$19M |
| 3 |
AG
Artal Group
Luxembourg
|
+$17.2M |
| 4 |
TCM
Tybourne Capital Management
Hong Kong
|
+$12.9M |
| 5 |
O
OrbiMed
New York
|
+$8.61M |
Top Sellers
NBTX Hedge Fund Activity: Q4 2020 in Review
11 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Nanobiotix (NBTX) for Q4 2020, worth a combined $81.3M.
Buyers outnumbered sellers: 11 funds opened new NBTX positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $24.1M.
- 11 institutional investors held Nanobiotix (NBTX) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $81.3M of Nanobiotix stock for Q4 2020.
- 11 funds opened new Nanobiotix positions in Q4 2020 and 0 closed out, a net change of +11 holders.
- The largest Nanobiotix buyer in Q4 2020 was Baillie Gifford & Co, an estimated $24.1M added.
Based on aggregated 13F filings for Q4 2020.